Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma

• Status: Completed
• Trial end date: 2007-01-01
• Target enrollment: 0
• Participant gender: All

Summary

carboplatin and etoposide, followed by maintenance therapy with weekly paclitaxel in patients with poorly differentiated neuroendocrine carcinomas. We hope to identify a "standard treatment" for this unusual group of patients who are not usually eligible for clinical trials.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: SCRI Development Innovations, LLC
• Collaborator: Bristol-Myers Squibb
• Treatments: Albumin-Bound Paclitaxel; Carboplatin; Etoposide; Etoposide phosphate; Paclitaxel

Criteria

Inclusion Criteria:

To be included in this study, you must meet the following criteria:

• Metastatic poorly differentiated neuroendocrine carcinoma

• Unknown primary site

• Able to perform activities of daily living with minimal assistance

• Measurable or evaluable disease

• Adequate bone marrow, liver functions and kidney function

• No previous treatment with chemotherapy

• Understand the nature of this study and give written informed consent.

Exclusion Criteria:

You cannot participate in this study if any of the following apply to you:

• Age < 18 years

• Previous malignancy within five years

• Women pregnant or lactating

• Recent history of cardiovascular disease

• Meningeal metastases

Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.